Furthermore, it was shown, that serum levels of RANKL and its decoy receptor OPG are deregulated in BRCA1-mutation carriers, lower OPG serum levels being associated with an increased risk of breast cancer [66]. This evidence concerns the gene BRCA1 and breast cancer.